SGLT2i Reduces Hospitalizations, Mortality in Patients With Heart Failure

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a pivotal class of medications in the treatment of heart failure (HF). Their ability to reduce hospitalization and mortality has significantly impacted patient outcomes. Despite this, challenges persist in optimizing SGLT2i utilization, particularly in inpatient settings.

A collection of abstracts presented at the Heart Failure Society of America 2024 Annual Meeting delved into these challenges and explored the benefits of SGLT2i in the patient population.

Click here for more coverage of the Heart Failure Society of America 2024 Annual Meeting.

READ MORE: Cardiology Resource Center

Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for our free Drug Topics newsletter.

References

1. Chen B, Miller M, Chen D, et al. Increasing the utilization of SGLT2i prescriptions at discharge for heart failure patients: A resident-led quality-improvement initiative. Presented at: Heart Failure Society of America 2024 Annual Meeting; September 27-30, 2024; Atlanta, GA. Poster 1306-116.

2. Mir J. Sodium glucose cotransporter 2 inhibitors in heart failure: meta-analysis. Presented at: Heart Failure Society of America 2024 Annual Meeting; September 27-30, 2024; Atlanta, GA. Poster 1204-295.

3. Addo B. Dapagliflozin in heart failure: a comprehensive meta-analysis on functional capacity, symptoms, and safety outcomes. Presented at: Heart Failure Society of America 2024 Annual Meeting; September 27-30, 2024; Atlanta, GA. Poster 1244-039.